Home » Industry News
Industry News
Herbal Sex Supplements May Often Contain Viagra Ingredients
May. 11 | According to a study, herbal supplements aimed at improving men’s sexual abilities may often contain the active ingredients in erectile dysfunction pills such as Viagra. Additionally, researchers found that some of these over-the-counter herbal...
FDA Grants Fast Track Designation for Cubist’s Late-Stage Antibiotic Candidate
May. 8 | Cubist Pharmaceuticals, Inc. communicated that the U.S. Food and Drug Administration (FDA) granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease...
FDA Grants Breakthrough Status to Ofatumumab In Combination With Bendamustine As Cancer Drug
May. 6 | Genmab A/S communicated the top-line results from a Phase II study of ofatumumab in combination with bendamustine in patients with untreated or relapsed chronic lymphocytic leukemia (CLL). A total of 97 patients were treated in the study and 87% of patients...
FDA Approved Second Simplist Drug Of Becton, Dickinson and Company
Apr. 29 | BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company), communicated that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched...
FDA Approved New Oral Contraceptive
Apr. 28 | Warner Chilcott plc communicated that the United States Food and Drug Administration (FDA) approved MINASTRINTM 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for the prevention of pregnancy. MINASTRIN 24 FE...
FDA Gave Lambrolizumab (MK-3475) of Merck “Breakthrough” Designation
Apr. 28 | Merck, known as MSD outside the United States and Canada, communicated that the U.S. Food and Drug Administration (FDA) designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is...
Bayer HealthCare Initiated Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T)
Apr. 22 | Bayer HealthCare Pharmaceuticals Inc. communicated that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated...
Eli Lilly and Company Announced Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes
Apr. 21 | Eli Lilly and Company announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary...
FDA Approved Topicort Topical Spray Of Taro Pharmaceutical Industries Ltd.
Apr. 21 | Taro Pharmaceutical Industries Ltd. (TARO) reported that it received approval from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application (“NDA”) Topicort (desoximetasone) Topical Spray, 0.25%. Topicort (desoximetasone) Topical...
.
